Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes
- 5 August 2021
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (16) , 2167-2179
Abstract
In the last several decades, fueled by gene knockout and knockdown techniques, there has been substantial progress in detailing the pathways of gluconeogenesis. A host of molecules have been identi...Keywords
Funding Information
- The Association of Diabetes Investigators
- The Rose Salter Medical Research Foundation
This publication has 150 references indexed in Scilit:
- FAM3A is a target gene of peroxisome proliferator-activated receptor gammaBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin SensitizerClinical Pharmacology & Therapeutics, 2013
- Selective ATP-Competitive Inhibitors of TOR Suppress Rapamycin-Insensitive Function of TORC2 in Saccharomyces cerevisiaeACS Chemical Biology, 2012
- Akt isoforms and glucose homeostasis – the leptin connectionTrends in Endocrinology & Metabolism, 2011
- Peroxisome Proliferator-Activated Receptor Alpha Target GenesPPAR Research, 2010
- AMP-activated protein kinase and its downstream transcriptional pathwaysCellular and Molecular Life Sciences, 2010
- PDX-1 interaction and regulation of the Pancreatic Derived Factor (PANDER, FAM3B) promoterBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2008
- MAP kinase pathways: The first twenty yearsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- The CREB coactivator TORC2 is a key regulator of fasting glucose metabolismNature, 2005
- THE WNT SIGNALING PATHWAY IN DEVELOPMENT AND DISEASEAnnual Review of Cell and Developmental Biology, 2004